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Background: Liver function tests (LFTs) can be affected by many factors and the proposed effects of coffee on LFT
require a comprehensive evaluation. The aim of this study was to elucidate whether drinking coffee, smoking, or
drinking alcohol have independent effects on LFTs in Korean health-check examinees.
Methods: We used the responses of 500 health-check examinees, who had participated in a self-administered
questionnaire survey about coffee, alcohol drinking, and smoking habits.
Results: Coffee consumption was closely related to male gender, high body mass index (BMI), alcohol drinking, and
smoking. On univariable and multivariable analyses, drinking coffee lowered serum levels of total protein, albumin,
and aspartate aminotransferases (AST). On multivariable analyses, smoking raised serum γ-glutamyl transferase (GGT)
level and decreased serum protein and albumin levels, while alcohol drinking raised GGT level after adjustment for
age, gender, regular medication, BMI, coffee and alcohol drinking amounts, and smoking.
Conclusions: Coffee consumption, smoking, and alcohol drinking affect the individual components of LFT in
different ways, and the above 3 habits each have an impact on LFTs. Therefore, their effects on LFTs should be
carefully interpreted, and further study on the mechanism of the effects is warranted.
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Liver function tests (LFT) are useful tools in clinical
practice to assess potential liver diseases, to monitor
treatment responses, and to predict prognosis of the
patients with liver diseases. As a battery, LFTs consists
most commonly of serum total cholesterol (TC), total
protein, albumin, alkaline phosphatase (ALP), total bili-
rubin (TB), aspartate amino transferase (AST), alanine
aminotransferase (ALT), and γ-glutamyl transferase
(GGT). However, the interpretation of LFTs should
be comprehensive and careful because LFTs can be
influenced by many personal and environmental factors,
including age, gender [1], body mass index (BMI) [2],* Correspondence: jsh@snubh.org
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reproduction in any medium, provided the oralcohol drinking [3], cigarette smoking, malnutrition,
presence of extrahepatic diseases such as cardiac, mus-
culoskeletal, or endocrine diseases, and status of liver
health in itself [4].
Although the influence of alcohol drinking on the liver
function has been extensively studied, studies on the
effects of coffee drinking or cigarette smoking have been
relatively limited. According to the international coffee
organization, people drink approximately 2.25 billion
cups of coffee everyday across the globe, and Korea is
the 11th highest coffee consuming country in the world,
consuming 65 thousand tons of coffee a year. Consider-
ing the large amounts of consumed coffee globally and
its lifetime consumption in most individuals, the effects
of coffee on health merit great attention. Interestingly,
coffee has been suggested to have a potential favorable
impact on liver diseases. In North America and Europe,
studies have shown that coffee drinking reduces the riskd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[5,6]. In addition, the protective effect of coffee drinking
on the development of HCC has been reported in the
Japanese [7]. Moreover, coffee consumption was inversely
related with serum levels of ALT and GGT among LFT,
especially in heavy alcohol drinkers [8].
Recently, it has been suggested that smoking increases
GGT and boosts the alcohol-induced GGT elevations
[9]. Although smoking does not damage hepatocytes
directly, it may change the effect of alcohol drinking on
AST, ALT and GGT activities via the actions of numerous
ingredients that alter the activities of enzymes found in
the liver [10]. Furthermore, smoking increased serum ALP
levels [11] produced by the bone and the kidney, as well as
by the liver. However, it is still not clear whether smoking
is related to each component of LFTs and whether the
effects are independent of alcohol drinking, since the
smoking habit itself is closely related to the alcohol drink-
ing habit [12]. Therefore, LFT changes in real clinical
situations need to be interpreted carefully in the context
of the interaction between various life style factors.
Nevertheless, most previous studies deal with the sep-
arate effects of alcohol, coffee, or smoking on one or a
few components of LFTs, and there has been a lack of
data on the comprehensive effects of alcohol, smoking
and coffee drinking on the commonly used all compo-
nents of LFTs. Moreover, those studies have been
reported primarily from Western countries and Japan,
while the study of the effects of these behaviors on LFTs
for persons living in Asian countries have had limited
study. Thus, this study was conducted in a Korean popu-
lation to evaluate the effects of coffee consumption,
smoking, and alcohol drinking on the most commonly
used sets of LFTs in order to consider the interactive
association with major demographic factors.Methods
Patients
In this cross-sectional study, all health-check examinees
were consecutively enrolled in the health promotion
center of Seoul National University Bundang Hospital
from August 2007 to October 2007. Of 909 examinees
during this study period, 500 (55%) subjects agreed to
participate to a comprehensive self-administered ques-
tionnaire survey about smoking, alcohol consumption,
and coffee drinking habits. Moreover, they were requested
to answer the questions about their current diseases
undergoing medical care, their past histories of hyperten-
sion, of diabetes mellitus, of hypercholesterolemia, or of
any other unspecified diseases and regular medications,
in order to discern the effects of regular medication on
serum LFTs. This study was approved by the Institutional
Review Board of Seoul National University BundangHospital and all participants provided written informed
consent prior to this study.
Questionnaire
Detailed information on each subject’s demographics,
medical history, physical findings, and laboratory results
were obtained from medical records. The information
on coffee and alcohol consumption, and cigarette smok-
ing habits was collected from the self-reported question-
naire survey (Additional file 1). Coffee consumers were
classified as ‘none’, ‘past’, or ‘current drinker’. If a subject
was a past or current drinker, information on total dur-
ation of coffee drinking and the daily amount of coffee
consumed were requested. The types of the most con-
sumed coffee were divided into 4 groups: instant, brewed,
a combination of instant and brewed coffee, and others.
The information about the duration of coffee consumption
was obtained through an open question (years). The fre-
quency and amount of coffee consumption was asked by
closed-ended question with 9 options (No, < 1 cup/month,
2–3 cups/month, a cup/week, 2–3 cups/week, 4–6 cups/
week, 1–2 cups/day, 3–4 cups/day, > 5 cups/day).
Alcohol drinking status was classified as none, past, or
current drinker and information on the detailed alcohol
drinking duration and daily amount of consumed alco-
holic beverages were obtained with similar way to those
of coffee consumption. Since an alcoholic consumption
of more than 60 g/day in men (20 g/day in women) over
more than 10 years has been documented as a major risk
factor for alcoholic liver disease [13], we categorized
alcohol drinkers according to their mean daily drinking
amounts into none, not-heavy (<60 g/day in men, <20 g/day
in women), and heavy (≥60 g/day in men, ≥20 g/day
in women) drinkers, and into never, mild (<100 × 103 g
in men, <35 × 103 g in women), moderate (100–200 ×
103 g in men, 35–70 × 103 g in women), and heavy life-
time drinkers (≥ 200 × 103 g in men, ≥70 × 103 g in
women), according to their lifetime drinking amounts
which were calculated based on the number of years that
a person had been drinking and the daily amounts of
alcohol consumption.
Smoking histories were classified in a similar manner
as above, participants were asked about their mean
cigarette amounts (packs) smoked per day over the
previous 6 months and the number of years having
smoked. Then, participants were classified into none,
mild (<0.5 pack/day), moderate (0.5-1 pack/day), and
heavy daily smokers (> 1 packs/day) and into never, mild
(<10 pack-years), moderate (10–20 pack-years), and
heavy (≥20 pack-years) lifetime smokers.
Physical and biochemical measurements
The height and weight of each participant were mea-
sured in order to calculate BMI. Biochemical assays for
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and GGT were performed in all subjects. The serologic
status of chronic viral hepatitis was evaluated by assays
for hepatitis B surface antigen (HBsAg)/antibody
(HBsAb) and anti-hepatitis C virus antibody (anti-HCV).
All assays were performed at the laboratory of Seoul
National University Bundang Hospital, which complied
with the International Federation of Clinical Chemistry
and Laboratory Medicine. We performed abdominal
sonography in all subjects, which was included in the
routine health-check program of our hospital.
Statistical analysis
The LFTs were recorded as continuous variables, but
serum GGT level was transformed to a natural logarith-
mic scale to normalize its non-standard distribution. To
compare baseline characteristics of subgroups, univari-
able analyses were performed using Student T tests or
analysis of variance (ANOVA) for continuous variables
and χ2 or tests for trend using linear-by linear associ-
ation for categorized variables.
Estimated means and 95% confidence intervals(CI) for
each LFT result were calculated from multivariable lin-
ear regression models after adjustment for age, gender,
BMI, regular medication for hypertension/diabetes
mellitus/hypercholesterolemia, daily alcohol drinking
(none, male (M) < 60 g or female (F) < 20 g, M ≥ 60 g
or F ≥ 20 g), and smoking (none, < 0.5 pack, 0.5-1 pack,
>1 packs) histories to determine the association between
coffee drinking and each LFT test result. To estimate
independent effects of alcohol or smoking on LFTs,
the same multivariable analyses were performed after
adjustment for daily coffee consumption amounts
(none, < 1 cup, 1–2 cups, ≥ 3 cups), and smoking or
alcohol drinking amounts, separately.
All statistical analyses were performed using SPSS
17.0 (SPSS Institute, Inc.; Chicago, IL, USA) software.
A P-value of <0.05 was considered statistically signifi-
cant on all analyses.
Results
Baseline characteristics of participants
The mean age of all participants (n=500) was 46.5 years.
Mean BMI was 23.5 kg/m2 and 144 (28.8%) were obese
(BMI ≥ 25 kg/m2) [14]. HBsAg was positive in 19 (3.8%)
subjects and anti-HCV was detected in 1 (0.2%) subjects,
however, viral loads of those subjects were not detect-
able. Fatty liver on the ultrasonography was detected in
46 (9.2%) participants.
A total of 443 (88.6%) participants were coffee drin-
kers at the time of the study and only 38 (7.6%) were
never-coffee drinkers (Table 1), and more than half of
Korean coffee drinkers preferred instant coffee (57.8%) to
brewed (8.0%, Table 1). The comparison of demographics,alcohol drinking, and smoking patterns among coffee con-
sumer groups categorized by daily coffee amounts was
summarized in Table 2. Interestingly, coffee consumption
was closely related to alcohol drinking and smoking
habits. As shown in Table 2, heavy coffee consumers
were more often current alcohol drinkers, and more
often heavy daily smokers. The interaction was more
consistent between coffee consumption and smoking
than between coffee consumption and alcohol drinking.
The association between coffee consumption and LFTs
The results of univariable analyses on the association
between daily amount of coffee consumption, smoking,
or alcohol drinking and each individual test of LFT are
summarized in Table 3.
Among the tests, serum total protein, albumin and
AST levels were significantly affected by coffee con-
sumption according to univariable analysis. Then, we
performed multivariable analyses on the association
between the coffee consumption and LFT changes. The
results are summarized in Table 4, showing that current
coffee drinkers had significantly lower serum total pro-
tein, albumin and ALP levels compared with never or
past coffee drinkers. Among the current coffee consu-
mers, heavy daily coffee drinkers (≥3 cups/day) showed
significantly lower levels of serum total protein, albumin
and AST levels. Moreover, heavy lifetime coffee drinkers
(>20,000 cups/lifetime) showed significantly lower levels
of TC, total protein, total albumin and AST, while ALT
or GGT was not associated independently with coffee
consumption history or total amounts after adjustments.
The association between smoking and LFTs
Of 500 participants, 119 (24.2%) were current smokers
(Table 1). In univariable analyses, the serum levels of
total protein, AST, ALT, GGT, and TB were significantly
affected by daily smoking amounts. Total protein level
decreased as daily smoking amounts increased, while
AST, ALT, and GGT levels increased as daily smoking
amount increased (Table 3).
In the multivariable models adjusted for age, gender,
BMI, regular medication, daily amounts of alcohol and
coffee drinking, current smokers had significantly lower
serum levels of total protein, and albumin, but higher
GGT levels compared with never or past smokers
(Table 5). In addition, daily and lifetime smoking
amounts significantly affected serum total protein, albu-
min, and GGT levels, but did not affect AST or ALT
(Table 5).
The association between alcohol and LFTs
Of our study population, 173 (34.6%) did not drink alco-
holic beverages, 19 (3.8%) had quit drinking, and 308
(61.6%) were current alcohol drinkers (Table 1). In
Table 1 Baseline characteristics of study population
Total Male Female p-value*
N=500 n=268 n=232
Agea, years 46.5 (10.8) 46.7 (10.8) 46.2 (10.8) 0.432
BMIa, kg/m2 23.5 (3.4) 24.5 (3.5) 22.3 (2.9) <0.001
Obesity (BMI≥25)b 144 (28.8) 107 (39.9) 37 (15.9) <0.001
Overweight (BMI ≥23)b 269 (53.8) 190 (70.9) 79 (34.1) <0.001
Regular medicationb 83 (16.6) 50 (18.7) 33 (14.2) 0.188
Anti-hypertensive drug 69 (13.8) 42 (15.7) 27 (11.7) 0.242
Oral hypoglycemic agent 9 (1.8) 7 (2.6) 2 (0.9) 0.186
Anti-hypercholesterolemic drug 13 (2.6) 7 (2.6) 6 (2.6) 1.000
Ultrasonographyb
Fatty liver 46 (9.2) 37 (13.8) 9 (3.9) <0.001
Liver function testsa
Total cholesterol, mg/dL 198.4 (35.2) 201.6 (33.9) 194.9 (36.3) 0.030
Total protein, g/dL 7.11 (0.37) 7.11 (0.36) 7.11 (0.39) 0.970
Albumin, g/dL 4.44 (0.24) 4.50 (0.24) 3.38 (0.22) <0.001
Total bilirubin, mg/dL 1.07 (0.41) 1.17 (0.38) 0.96 (0.41) <0.001
ALP, IU/L 63.2 (18.6) 65.3 (15.9) 60.8 (21.1) 0.008
AST, IU/L 24.3 (12.4) 25.8 (11.8) 22.6 (12.8) 0.005
ALT, IU/L 25.8 (18.0) 30.7 (18.0) 20.1 (16.3) <0.001
GGT, IU/L 35.3 (39.4) 46.0 (35.7) 33.9 (39.9) <0.001
Ln(GGT) 3.25 (0.72) 3.60 (0.64) 2.83 (0.58) <0.001
Coffee
Drinking historyb
None drinker 38 (7.6) 19 (7.1) 19 (8.2) 0.525†
Past drinker, quitted 19 (3.8) 9 (3.4) 10 (4.3)
Current drinker 443 (88.6) 240 (89.6) 203 (87.5)
Type of coffeeb
Instant 289 (57.8) 164 (61.2) 125 (53.9) 0.084†
Brewed 40 (8.0) 21 (7.8) 19 (8.2)
Instant and brewed (mixed) 66 (13.2) 33 (12.3) 33 (14.2)
Others 105 (21.0) 50 (18.7) 55 (23.7)
Daily amount of coffee consumption (cups/day)b
0 43 (8.6) 22 (8.2) 21 (9.1) 0.001†
<1 109 (21.8) 51 (19.0) 58 (25.0)
1-2 229 (45.6) 108 (40.3) 120 (51.7)
≥ 3 120 (24.0) 87 (32.5) 33 (14.2)
Smoking
Historyb
None smoker 262 (53.3) 50 (18.7) 212 (94.2) <0.001†
Past smoker, quitted 111 (22.6) 109 (40.8) 2 (0.9)
Current smoker 119 (24.2) 108 (40.4) 11 (4.9)
Daily smoking amount (packs/day)b n=473 n=249 n=224
No 262 (55.4) 50 (20.1) 212 (94.6) <0.001†
<0.5 76 (16.1) 66 (26.5) 10 (4.5)
0.5-1 96 (20.3) 94 (37.8) 2 (0.9)
> 1 39 (8.2) 39 (15.7) 0 (0.0)
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Alcohol
Drinking historyb
None drinker 173 (34.6) 32 (11.9) 141 (60.8) <0.001†
Past drinker, quitted 19 (3.8) 13 (4.9) 6 (2.6)
Current drinker 308 (61.6) 223 (83.2) 85 (36.6)
Daily amount of alcohol consumptionb
No 180 (36.0) 34 (12.7) 146 (62.9) <0.001†
Not heavy (< 60g/day for male, <20g/day for female) 290 (58.0) 213 (79.5) 77 (33.2)
Heavy (≥ 60 g/day for male, ≥20 g/day for female) 30 (6.0) 21 (7.8) 9 (3.9)
Duration of drinkingb
≥ 10 years 236 (49.4) 203 (76.0) 43 (18.6) <0.001
Abbreviation:BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ln(GGT), natural logarithmic scale
of gamma-glutamyltransferase.
a Data are presented as mean (SD).
b Data are presented as number (%).
* P-value for the comparison between men and women.
† P for trend.
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associated with lower levels of serum albumin and high
levels serum AST, ALT, GGT and TB levels (Table 3).
However, the increases in AST and ALT levels as the
result of daily alcohol consumption did not maintain
statistical significance after multivariable adjustments for
age, gender, BMI, regular medication, coffee drinking,
and smoking (Table 6), which showed that primarily
ALP and GGT were affected by alcohol drinking. As
shown in Table 6, mean adjusted ALP levels were
affected by current alcohol drinking and heavy lifetime
drinking amounts; however, these effects did not demon-
strate a consistent tendency or pattern. GGT levels were
undoubtedly increased in current drinkers and in heavy
daily drinkers, as well as in heavy lifetime alcohol drin-
kers (Table 6).Discussion
In the present study, strong correlations existed among
coffee consumption, alcohol drinking and smoking
habits. The associations between those lifestyle habits
and LFTs were investigated using multivariable analyses:
coffee drinking was significantly associated with lower
levels of serum total protein, albumin, and AST, but did
not affect TC, ALT, GGT and TB. In addition, cigarette
smoking diminished serum total protein and albumin,
whereas it raised GGT levels independently. Alcohol
drinking independently raised GGT levels. As our best
knowledge, this is the first study that demonstrated in-
dependent effects of coffee drinking, smoking and alco-
hol consumption on the comprehensive LFTs commonly
used in humans. Several previous studies included only
limited test items in LFT and their associations with
each of the variables (alcohol, smoking or coffeedrinking), but not with all of these common lifestyle
habits were reported.
We demonstrated that total protein and albumin levels
were decreased by both coffee drinking and smoking.
The decrease of serum protein and albumin levels
according to increase of daily coffee consumption
amount was also confirmed in subjects who had never
drunken alcohol nor smoked in the present study (data
not shown). Although most previous studies had not
mentioned total protein or albumin levels, a study docu-
mented that current or past coffee consumption and
smoking lower serum albumin, globulin, and all other
protein fractions [15]. Moreover, in the chronic hepatitis
patients, current smokers were more likely to have lower
albumin levels than nonsmokers [16]. However, the bio-
logical mechanisms leading to decreased levels of serum
protein and albumin by coffee drinking and smoking
have not been studied, yet.
Previous epidemiological studies suggested a hepato-
protective effect of coffee drinking on liver function [17].
Furthermore, the protective effects of coffee consump-
tion on AST and ALT have been reported especially in
heavy alcohol drinkers [8]. In contrast, several prospect-
ive experimental studies demonstrated rather elevated
AST and ALT levels after administration of coffee or its
ingredient (cafestol) in human subjects, as well as in ani-
mal studies [18]. In our study, the heavy alcohol drinkers
were only 9.3% of the total subjects, and we could not
ascertain the protective effect of coffee on the AST or
ALT changes related with alcohol drinking. Although
GGT is a sensitive indicator of liver disease, its specifi-
city is not high enough, since numerous environmental
factors and drugs can elevate GGT. Coffee has been
implicated to reduce GGT concentration because its
anti-oxidant ingredients may preserve intracellular
Table 2 Comparison of characteristics among coffee consumer groups categorized by daily coffee amounts
Daily coffee drinking amount
No Mild Moderate Heavy
0 cup/day <1 cup/day 1-2 cup/day ≥3 cup/day
n=43 n=109 n=228 n=120 p-value
Agea, years 48.5 (12.7) 44.6 (12.3) 47.4 (9.7) 45.7 (10.3) 0.077
Maleb 22 (51.2) 51 (46.8) 108 (47.4) 87 (72.5) 0.001
BMIa 23.2 (2.8) 23.4 (3.1) 23.1 (3.1) 24.2 (4.0) 0.035
Obesity (BMI≥25 kg/m2)b 11 (25.6) 26 (23.9) 63 (27.6) 44 (36.7) 0.152
Regular medicationb 8 (18.6) 20 (18.3) 39 (17.1) 16 (13.3) 0.305
Anti-hypertensive drug 7 (16.3) 19 (17.4) 29 (12.8) 14 (11.7) 0.206
Oral hypoglycemic agent 2 (4.7) 1 (0.9) 5 (2.2) 1 (0.8) 0.313
Anti-dyslipidemic drug 1 (2.3) 4 (3.7) 7 (3.1) 1 (0.8) 0.332
Ultrasonography
Fatty liverb 2 (4.7) 13 (11.9) 17 (7.5) 14 (11.8) 0.480
Alcohol
Drinking historyb
None drinker 22 (51.2) 37 (33.9) 81 (35.5) 33 (27.5) 0.007†
Past drinker, quitted 3 (7.0) 7 (6.4) 5 (2.2) 4 (3.3)
Current drinker 18 (41.9) 65 (59.6) 142 (62.3) 83 (69.2)
Daily amount of alcohol consumptionb 15.9 (40.9) 11.1 (19.9) 14.0 (34.9) 16.0 (27.1) 0.649
No 22 (51.2) 40 (36.7) 83 (36.4) 35 (29.2) 0.086†
Not heavy (< 60g/day for male, <20g/day for female) 17 (39.5) 63 (57.8) 131 (57.5) 79 (65.8)
Heavy (≥ 60 g/day for male, ≥20 g/day for female) 4 (9.3) 6 (5.5) 14 (6.1) 6 (5.0)
Duration of drinkingb n=43 n=106 n=227 n=116
≥ 10 years 17 (39.5) 41 (38.7) 119 (52.4) 71 (61.2) 0.001
Lifetime amount (x103 g)b n=43 n=106 n=227 n=118
Never 22 (51.2) 38 (35.8) 80 (35.2) 33 (28.0) 0.033†
Mild(<100 x103 g for male , <35 x103 g for female) 12 (27.9) 44 (41.5) 82 (36.1) 47 (39.8)
Moderate (100–200 x103 g for male, 35–70 x103 g for female) 1 (2.3) 7 (6.6) 19 (8.4) 13 (11.0)
Heavy (≥200 x103 g for male, ≥70 x103 g for female) 8 (18.6) 17 (16.0) 46 (20.3) 25 (21.2)
Smoking
Historyb n=42 n=107 n=223 n=120
None smoker 28 (66.7) 72 (67.3) 131 (58.7) 31 (25.8) <0.001†
Past smoker, quitted 10 (23.8) 16 (15.0) 53 (23.8) 32 (26.7)
Current smoker 4 (9.5) 19 (17.8) 39 (17.5) 57 (47.5)
Daily smoking amount (packs/day)b n=42 n=105 n=213 n=113
No 28 (66.7) 72 (68.6) 131 (61.5) 31 (27.4) <0.001†
<0.5 7 (16.7) 13 (12.4) 33 (15.5) 23 (20.4)
0.5-1 4 (9.5) 16 (15.2) 34 (16.0) 42 (37.2)
> 1 3 (7.1) 4 (3.8) 15 (7.0) 17 (15.0)
Lifetime amount (pack-year)b n=39 n=96 n=199 n=99
Never 28 (71.8) 72 (75.0) 131 (65.8) 31 (31.3) <0.001†
<10 5 (12.8) 12 (12.5) 27 (13.6) 15 (15.2)
10-20 1 (2.6) 3 (3.1) 23 (11.6) 30 (30.3)
≥ 20 5 (12.8) 9 (9.4) 18 (9.0) 23 (23.2)
Abbreviation: BMI, body mass index.
a Data are presented as mean (SD).
b Data are presented as number (%).
* P-value for the comparison among the daily coffee consumer groups (no, <1 cups/day, 1–2 cups/day, ≥3 cups/day).
† P for trend.
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Daily coffee drinking amount
(cups/day)
No 43 197.5 (38.9) 7.29 (0.36) 4.55 (0.25) 70.2 (23.0) 24.6 (7.8) 25.4 (13.1) 3.22 (0.68) 1.05 (0.40)
Mild (<1) 109 194.4 (30.9) 7.13 (0.35) 4.44 (0.26) 62.5 (15.2) 27.4 (20.7) 28.2 (25.9) 3.18 (0.78) 1.09 (0.43)
Moderate (1–2) 228 198.2 (36.9) 7.10 (0.39) 4.43 (0.22) 61.9 (19.6) 23.1 (8.9) 23.8 (14.8) 3.20 (0.68) 1.08 (0.42)
Heavy (≥3) 120 202.8 (33.9) 7.04 (0.35) 4.44 (0.23) 63.7 (17.3) 23.7 (8.3) 27.6 (15.9) 3.40 (0.75) 1.06 (0.37)
p-value 0.344 0.002 0.025 0.057 0.029 0.111 0.051 0.888
Daily smoking amount
(pack/day)
No 262 196.2 (36.3) 7.16 (0.39) 4.43 (0.23) 61.4 (20.0) 22.3 (7.5) 21.3 (14.3) 2.93 (0.61) 1.00 (0.39)
Mild (<0.5) 76 200.1 (32.4) 7.07 (0.37) 4.48 (0.35) 62.8 (15.3) 27.3 (22.7) 30.2 (22.8) 3.51 (0.76) 1.18 (0.45)
Moderate (0.5-1) 96 200.1 (34.7) 7.03 (0.35) 4.46 (0.24) 66.6 (17.1) 25.5 (10.0) 31.8 (20.3) 3.63 (0.65) 1.15 (0.39)
Heavy (>1) 39 203.5 (30.5) 7.04 (0.34) 4.43 (0.20) 64.0 (15.6) 25.8 (9.4) 30.8 (17.9) 3.82 (0.61) 1.09 (0.32)
p-value 0.524 0.01 0.344 0.124 0.003 <0.001 <0.001 <0.001
Daily drinking amount
(g/day)
No 180 200.5 (34.1) 7.14 (0.35) 4.41 (0.22) 64.9 (21.4) 24.3 (14.3) 23.0 (17.3) 2.93 (0.57) 0.97 (0.36)
Not heavy
(< 60g/day for male,
<20g/day for female)
290 196.7 (35.5) 7.09 (0.39) 4.47 (0.24) 61.9 (15.7) 23.7 (8.2) 26.5 (16.7) 3.36 (0.68) 1.13 (0.42)
Heavy
( ≥ 60 g/day for male,
≥20 g/day for female)
30 203.2 (37.7) 7.12 (0.38) 4.43 (0.24) 65.2 (25.3) 30.5 (25.7) 35.6 (28.1) 4.08 (0.94) 1.17 (0.45)
p-value 0.394 0.369 0.03 0.198 0.016 0.001 <0.001 <0.001
Abbreviation:AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ln(GGT), natural logarithmic scale of gamma-glutamyltransferase.




























AST, IU/L ALT, IU/L Ln(GGT) Total bilirubin,
mg/dL
1) History of coffee
None drinker 37 197.0 (184.4, 209.6) 7.24 (7.11, 7.48) 4.52 (4.44, 4.60) 68.7 (62.0, 75.1) 26.6 (22.2, 30.9) 28.8 (22.7, 35.0) 3.51 (3.30, 3.72) 1.01 (0.87, 1.15)
Past drinker, quitted 19 189.8 (173.3, 206.4) 7.20 (7.02, 7.37) 4.52 (4.42, 4.63) 72.7 (64.1, 81.3) 25.8 (20.1, 31.4) 27.5 (19.4, 35.6) 3.47 (3.19, 3.75) 0.99 (0.80, 1.18)
Current drinker 436 198.9 (192.2, 205.6) 7.07 (7.00, 7.14) * 4.42 (4.38, 4.46) * 63.9 (60.4, 67.4) 26.6 (24.4, 28.9) 29.0 (25.7, 32.2) 3.52 (3.40, 3.63) 1.08 (1.00, 1.15)
p for trend 492 0.528 0.003 0.003 0.042 0.898 0.879 0.859 0.221
2) Daily amount of coffee consumption (cups/day)
No 42 195.7 (183.7, 207.7) 7.26 (7.13, 7.38) 4.53 (4.45, 4.61) 70.5 (64.2, 76.7) 26.5 (22.5, 30.5) 28.9 (23.1, 34.7) 3.51 (3.31, 3.71) 1.02 (0.88, 1.15)
<1 107 196.4 (187.5, 205.4) 7.10 (7.00, 7.20) * 4.43 (4.37, 4.48) * 65.5 (60.8, 70.2) 31.3 (28.3, 34.3)* 33.2 (28.8, 37.5) 3.54 (3.39, 3.69) 1.11 (1.01, 1.21)
1-2 223 197.8 (190.3, 205.3) 7.09 (8.01, 7.17) * 4.43 (4.38, 4.48) * 63.7 (59.8, 67.6) * 25.6 (23.1, 28.1) 27.8 (24.2, 31.4) 3.52 (3.40, 3.65) 1.09 (1.00, 1.18)
≥3 120 200.9 (192.4, 209.4) 7.04 (6.95, 7.13) * 4.42 (4.37, 4.48) * 64.1 (59.7, 68.5) * 25.1 (22.2, 27.9) 27.7 (23.6, 31.9) 3.49 (3.35, 3.63) 1.03 (0.93, 1.13)
p for trend 492 0.326 0.005 0.048 0.068 0.006 0.088 0.733 0.691
3) Duration of coffee drinking (years)
Never 37 196.6 (184.0, 209.1) 7.25 (7.11, 7.38) 4.52 (4.44, 4.60) 69.1 (62.5, 75.6) 26.6 (22.3, 30.9) 28.7 (22.5, 34.8) 3.50 (3.30, 3.71) 1.00 (0.87, 1.15)
<10 93 191.9 (182.5, 201.3) 7.06 (6.96, 7.17) * 4.45 (4.39, 4.51) 68.2 (63.3, 73.1) 27.9 (24.7, 31.1) 28.6 (23.9, 33.2) 3.43 (3.29, 3.59) 1.08 (0.97, 1.19)
11-29 299 198.9 (192.0, 205.9) 7.08 (7.00, 7.15) * 4.43 (4.38, 4.47) * 63.3 (59.6, 67.0) 26.6 (24.3, 29.0) 29.7 (26.3, 33.0) 3.55 (3.43, 3.66) 1.07 (0.99, 1.15)
≥30 59 203.0 (191.6, 214.3) 7.11 (6.99, 7.24) 4.41 (4.33, 4.48) * 65.3 (59.4, 71.2) 24.6 (20.7, 28.5) 25.1 (19.6, 30.7) 3.45 (3.26, 3.64) 1.10 (0.97, 1.23)
p for trend 488 0.132 0.144 0.013 0.046 0.295 0.633 0.642 0.396
4) Lifetime amount of coffee consumption (cups)
0 42 195.0 (183.1, 207.0) 7.25 (7.13, 7.38) 4.53 (4.45, 4.61) 70.4 (64.2, 76.6) 26.6 (22.5, 30.6) 28.9 (23.1, 34.8) 3.51 (3.30, 3.71) 1.02 (0.88, 1.15)
1-10000 233 194.2 (186.5, 201.9) 7.12 (7.04, 7.20) * 4.44 (4.39, 4.49) * 64.8 (60.8, 68.9) 29.0 (26.4, 31.6) 30.7 (27.0, 34.5) 3.53 (3.40, 3.66) 1.12 (1.03, 1.21)
10001-20000 139 198.5 (190.5, 206.5) 7.02 (6.93, 7.10) * 4.40 (4.35, 4.46) * 62.8 (58.6, 67.0) * 25.2 (22.5, 28.0) 27.9 (23.9, 31.8) 3.50 (3.37, 3.63) 1.04 (0.95, 1.13)
>20000 78 207.3 (196.5, 215.9) 7.08 (6.98, 7.19) * 4.44 (4.38, 4.50) * 65.2 (60.1, 70.3) 24.4 (21.2, 27.7) 27.2 (22.4, 31.9) 3.50 (3.34, 3.66) 1.05 (0.94, 1.16)
p for trend 492 0.029 0.005 0.046 0.155 0.015 0.18 0.737 0.428
Abbreviation:AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ln(GGT), natural logarithmic scale of gamma-glutamyltransferase.
a Data are presented as mean (95% C.I.). Estimated mean and 95% CI were calculated by using multivariable linear regression model adjusted for age, gender, body mass index, regular medication, daily alcohol
drinking (none, M < 60 g or F < 20 g, M ≥ 60 g or F ≥ 20 g) and smoking (none, < 0.5 pack, 0.5-1 pack, > 1 packs) amounts.


























AST, IU/L ALT, IU/L Ln(GGT) Total bilirubin,
mg/dL
1) History of smoking
None smoker 262 199.3 (192.1, 206.6) 7.25 (7.18, 7.33) 4.52 (4.47, 4.56) 65.2 (61.4, 69.0) 24.1 (21.7, 26.5) 26.0 (22.6, 29.5) 3.35 (3.23, 3.48) 1.07 (0.99, 1.15)
Past smoker, quitted 111 196.0 (186.6, 205.4) 7.17 (7.07, 7.27) 4.47 (4.41, 4.53) 63.3 (58.4, 68.2) 28.7 (25.6, 31.8) * 31.4 (27.0, 35.9) * 3.50 (3.35, 3.66) 1.15 (1.05, 1.26)
Current smoker 119 200.6 (191.4, 209.9) 7.02 (6.92, 7.11) * 4.41 (4.35, 4.46) * 69.8 (65.0, 74.6) 27.9 (24.9, 30.9) * 30.0 (35.6, 34.4) 3.58 (3.43, 3.73) * 1.02 (0.91, 1.12)
p for trend 492 0.672 <0.001 0.001 0.04 0.074 0.213 0.014 0.185
2) Daily amount of smoking (pack/day)
No 262 198.7 (191.3, 206.0) 7.26 (7.19, 7.34) 4.53 (4.48, 4.57) 64.9 (61.1, 68.7) 24.0 (21.6, 26.6) 26.0 (22.4, 29.5) 3.34 (3.22, 3.46) 1.07 (0.99, 1.16)
<0.5 76 197.8 (187.8, 207.8) 7.11 (7.00, 7.21) * 4.46 (4.40, 4.53) 65.0 (59.8, 70.3) 29.6 (26.3, 33.0) * 31.7 (26.9, 36.6) * 3.53 (3.36, 3.69) 1.11 (1.00, 1.22)
0.5-1 96 196.9 (186.9, 206.9) 7.06 (6.95, 7.17) * 4.42 (4.35, 4.48) * 69.1 (63.9, 74.3) 27.7 (24.3, 31.0) 31.3 (26.4, 36.1) 3.55 (3.39, 3.72) * 1.06 (0.95, 1.18)
> 1 39 197.5 (184.8, 210.1) 7.05 (6.92, 7.18) * 4.40 (4.32, 4.48) * 64.8 (58.1, 71.4) 27.1 (22.9, 31.3) 28.6 (22.5, 34.8) 3.64 (3.42, 3.85) * 0.99 (0.85, 1.14)
p for trend 473 0.806 0.002 0.001 0.502 0.265 0.319 0.013 0.327
3) Lifetime amount of smoking (pack*year)
Never 262 198.0 (190.5, 205.6) 7.27 (7.19, 7.35) 4.53 (4.48, 4.58) 65.2 (61.2, 69.1) 24.9 (22.7, 27.1) 26.2 (22.7, 29.7) 3.35 (3.22, 3.47) 1.07 (0.99, 1.16)
< 10 59 194.7 (183.9, 205.5) 7.08 (6.96, 7.19) * 4.44 (4.37, 4.51) * 68.3 (62.7, 74.0) 28.5 (25.4, 31.6) * 30.7 (25.7, 35.7) 3.52 (3.34, 3.70) 1.10 (0.98, 1.22)
10 - 20 57 199.7 (187.8, 211.6) 7.08 (6.95, 7.21) * 4.45 (4.37, 4.53) 71.6 (65.4, 77.7) 27.6 (24.2, 31.0) 28.4 (22.8, 33.9) 3.56 (3.36, 3.75) 1.12 (0.98, 1.25)
≥ 20 55 198.9 (187.2, 210.6) 6.99 (6.97, 7.12) * 4.38 (4.31, 3.36) * 66.1 (60.0, 72.2) 28.0 (24.7, 31.4) 33.1 (27.7, 38.6) * 3.59 (3.40, 3.78) * 0.95 (0.82, 1.08)
p for trend 433 0.755 <0.001 0.002 0.611 0.144 0.051 0.029 0.153
Abbreviation:AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ln(GGT), natural logarithmic scale of gamma-glutamyltransferase.
a Data are presented as mean (95% C.I.). Estimated mean and 95% CI were calculated by using multivariable linear regression model adjusted for age, gender, body mass index, regular medication, daily alcohol (none,
M < 60 g or F < 20 g, M ≥ 60 g or F ≥ 20 g) and coffee (none, < 1 cup, 1–2 cups, ≥ 3 cups) drinking amounts.




























AST, IU/L ALT, IU/L Ln(GGT) Total bilirubin,
mg/dL
1) History of alcohol drinking
None drinker 173 200.2 (192.0, 208.3) 7.13 (7.04, 7.21) 4.46 (4.41, 4.52) 68.6 (64.3, 72.9) 25.8 (23.0, 28.5) 28.7 (24.8, 32.7) 3.27 (3.13, 3.41) 1.00 (0.91, 1.10)
Past drinker, quit 19 189.2 (172.2, 206.4) 7.13 (6.94, 7.31) 4.49 (4.39, 4.60) 58.0 (49.2, 66.9) * 29.3 (23.5, 35.1) 28.6 (20.3, 37.0) 3.10 (2.81, 3.40) 1.00 (0.80, 1.19)
Current drinker 308 195.5 (188.7, 202.3) 7.08 (7.01, 7.16) 4.43 (4.39, 4.48) 64.0 (60.4, 67.5) * 25.0 (22.8, 27.3) 27.3 (24.0, 30.6) 3.43 (3.31, 3.55) * 1.07 (0.99, 1.14)
p for trend 500 0.269 0.291 0.225 0.037 0.514 0.441 0.016 0.156
2) Daily amount of alcohol (g)
No 180 199.8 (191.7, 207.9) 7.13 (7.05, 7.22) 4.46 (4.41, 4.52) 68.2 (63.9, 72.4) 26.7 (24.0, 29.5) 29.1 (35.1, 33.0) 3.23 (3.10, 3.37) 0.99 (0.89, 1.08)
Not heavy
(< 60g/day for male,
<20g/day for female)
290 194.1 (187.3, 200.9) 7.07 (7.00, 7.15) 4.44 (4.40, 4.48) 62.8 (59.3, 66.3) * 24.2 (21.9, 26.5) 26.3 (23.0, 29.6) 3.31 (3.20, 3.43) 1.06 (0.98, 1.13)
Heavy
(≥ 60 g/day for male,
≥20 g/day for female)
30 199.2 (185.8, 212.5) 7.15 (7.01, 7.30) 4.45 (4.37, 4.54) 66.8 (59.9, 73.8) 30.4 (25.9, 34.9) 32.8 (26.3, 39.3) 4.00 (3.77, 4.22) * 1.14 (0.99, 1.29)
p for trend 500 0.412 0.593 0.471 0.111 0.963 0.939 <0.001 0.041
3) Duration of alcohol drinking (years)
<10 258 195.7 (188.1, 203.3) 7.12 (7.04, 7.20) 4.46 (4.41, 4.51) 67.1 (36.1, 71.1) 25.6 (23.0, 28.1) 26.7 (23.0, 30.4) 3.22 (3.09, 3.35) 1.00 (0.92, 1.09)
≥ 10 236 197.1 (190.1, 204.2) 7.10 (7.02, 7.17) 4.45 (4.41, 4.50) 63.1 (59.4, 66.8) 25.7 (23.3, 28.1) 28.7 (25.3, 32.5) 3.46 (3.34, 3.58) * 1.08 (1.00, 1.16)
p for trend 494 0.725 0.616 0.807 0.057 0.918 0.289 0.001 0.111
4) Lifetime amount of alcohol (x103 g)
Never 173 200.1 (191.8, 208.4) 7.13 (7.04, 7.22) 4.47 (4.42, 4.52) 68.7 (64.3, 73.0) 25.5 (22.7, 28.3) 28.4 (24.4, 32.5) 3.20 (3.06, 3.34) 1.00 (0.90, 1.09)
Mild (<100 x103 g for male,
<35 x103 g for female)
185 193.0 (185.4, 200.6) 7.10 (7.02, 7.18) 4.56 (4.41, 4.50) 64.3 (60.3, 68.3) * 24.5 (22.0, 27.1) 27.5 (23.8, 31.2) 3.24 (3.11, 3.37) 1.07 (0.99, 1.09)
Moderate (100–200 x103 g for male,
35–70 x103 g for female)
40 203.6 (191.4, 215.8) 7.00 (6.87, 7.13) 4.44 (4.36, 4.51) 59.9 (53.5, 66.2) * 23.6 (19.5, 27.7) 23.4 (17.4, 29.3) 3.35 (3.14, 3.56) 0.97 (0.83, 1.11)
Heavy (≥200 x103 g for male,
≥70 x103 g for female)
96 195.4 (186.5, 204.3) 7.12 (7.02, 7.21) 4.44 (4.38, 4.50) 62.6 (58.0, 67.3) * 27.7 (24.7, 30.7) 38.8 (24.5, 33.1) 3.68 (3.53, 3.83) * 1.08 (0.98, 1.18)
p for trend 494 0.679 0.618 0.329 0.026 0.237 0.929 <0.001 0.316
Abbreviation:AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ln(GGT), natural logarithmic scale of gamma-glutamyltransferase.
a Data are presented as mean (95% C.I.). Estimated mean and 95% CI were calculated by using multivariable linear regression model adjusted for age, gender, body mass index, regular medication, daily coffee
drinking (none, < 1 cup, 1–2 cups, ≥ 3 cups) and smoking (none, < 0.5 pack, 0.5-1 pack, > 1 packs) amounts.
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http://www.biomedcentral.com/1471-230X/12/145homeostasis, which need GGT [19]. However, in our
study, GGT level was not independently associated with
coffee consumption after adjustment of age, gender,
BMI, alcohol and smoking. Alcohol drinking [3] and
smoking [20] were well known factors to raise GGT
levels. Although BMI is one of the most important fac-
tors resulting in GGT elevation [1], several previous
studies that have asserted the protective effect of coffee
on the GGT did not consider BMI in their estimations
[21]. Therefore, such confounding factors could provide
a false favorable effect of coffee consumption on the
serum GGT concentration.
The present study is the first to describe a detailed
effect of smoking on the individual test of LFTs. Previous
studies showed that current smokers revealed high GGT
compared to non-smokers [22] and people with high
GGT levels smoked more [23], which was compatible
with our results (Table 5). It was controversial whether
smoking could affect aminotransferase activities. Some
investigators claimed ALT was increased by smoking
[24], while recent studies argued that smoking did not in-
fluence AST or ALT, but GGT [25] as our results sup-
port. Although our multivariable results showed elevated
ALP levels in the current smoker compared to never hav-
ing smoked or past-smokers, it was not confirmed in the
daily or lifetime smoking amounts. Several studies con-
cerning osteoporosis have documented increased serum
ALP levels in current smokers, as a marker of bone turn-
over [26]. Therefore, the effects of smoking on ALP level
may be complicated with many extrahepatic mechanisms
that did not show a consistent association with smoking
in our study after adjustment of many factors.
It was interesting to observe the strong correlations
between coffee consumption, alcohol drinking, and
smoking habits in our study subjects. In addition, these
correlations have been documented in most prior studies
[27] suggesting that coffee drinkers are more likely to be
alcohol drinkers or cigarette smokers. Therefore, the
complete information about these habits is warranted to
analyze or interpret reasonably the effect of each habit
on LFTs.
In the present study, we carried out a survey on
health-check examinee volunteers who were eager to be
evaluated about their lifestyle and the effects on their
health status, and would provide almost complete
responses about alcohol drinking, smoking and coffee
consumption; this provided the opportunity to perform
a comprehensive analysis of the relationship of these
behaviors with LFTs. The strengths of our study
included an intensive data collection, and we distin-
guished participants who had quitted coffee, alcohol and
smoking (past users) from those with no history and
current users, which made it possible to gain informa-
tion about lifetime consumption amounts. An additionalstrength was that we presented independent effects of
coffee consumption, smoking, and alcohol drinking on
the most commonly used comprehensive items of LFTs,
adjusted by extensive confounding factors that included
age, gender, BMI, and regular medications. Nevertheless,
the lack of evidence of the causal-relationship between
lifestyle and LFT changes remained a limitation of our
study due to its cross-sectional design. In addition, some
heavy alcohol drinker or smoker might be excluded from
the present study since 45% of eligible patients refused
to respond to the questionnaire. Moreover, coffee-
consumption patterns, such as high frequency of instant
coffee consumption in Korea, might be a barrier to
generalize our results. As we mentioned above, 71% of
participants usually consumed instant coffee (57.8%, in-
stant coffee only; 13.2%, instant and brewed coffee,
Table 1). Most instant coffee on the market in Korea
contains cream and sugar, which is different from
brewed coffee that is the primary type of coffee con-
sumed in Western countries [28]. Information about
decaffeinated or caffeinated coffee consumption was not
recorded because decaffeinated coffee was rarely con-
sumed in Korea.
Conclusions
High coffee consumption and heavy smoking were both
associated with low total protein and albumin levels.
High coffee consumption lowered serum AST levels,
heavy smoking raised GGT levels, and heavy alcohol
drinking raised GGT levels, independently. Because
smoking, coffee and alcohol drinking habits showed
strong interactions among each other, the association of
those habits and LFTs should be carefully analyzed and
interpreted. Further studies on the mechanisms of these
associations are warranted.
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